| abstract |
The quinoxalinediones of formula I wherein R is a 5-membered ring heteroaryl containing 3 or 4 N atoms, which is attached to the quinoxalinedione ring via a C or N ring, or a 6-membered ring heteroaryl containing 1 to 3 N atoms, the quinoxalinedione ring attached through a ring C, optionally benzoated to each of these groups, and each of these groups, including fused benzo groups, optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl, alkenyl, cycloalkyl, halogen, hydroxyl, alkoxy , cycloalkyloxy, -COOH, alkoxycarbonyl, -CONR.sup.3.nRsup.4.n, -NR.sup.3.nRsup.4.n, -S (O) ssub-alkyl, -SO.sub.2-NR.sup.3-R.sup.4, aryl, aryloxy, arylalkoxy and heterocycle, wherein the alkyl or alkenyl is optionally further substituted; R.sup.1.n. and R.sup.2.n. each independently is H, F, Cl, Br, alkyl or haloalkyl; R.sup.3.n. and R.sup.4.n. is each independently H or alkyl, or taken together to represent alkylene; and p is 0, 1 or 2; and pharmaceutically acceptable salts thereof. Production method and intermediates for the production of these quinoxalinediones. Pharmaceutical compositions based on these compounds and their use in the treatment of neurodegenerative or chronic neurological disorders, e.g. |